
ICON (ICLR) Stock Forecast & Price Target
ICON (ICLR) Analyst Ratings
Bulls say
Icon has observed an 11% increase in gross business awards on a sequential basis, driven by significant wins from biotech customers and the ongoing expansion of large pharmaceutical partnerships formed in the past 18 months. The company has successfully met or exceeded its financial targets related to the PRA acquisition, positioning itself favorably amidst funding environment uncertainties with a strong client and business mix. Additionally, Icon is well-positioned to benefit from the growth in the contract research organization (CRO) market, evidenced by an improving win rate within its client segments.
Bears say
Icon has revised its EBITDA margin expectations downward for the coming years, projecting margins in the high-19% range instead of the previously anticipated ~20%, signaling potential pressure on profitability. Additionally, various downside risks, including slowed clinical trial activity due to pharmaceutical company reprioritizations and uncertainty surrounding biotech funding, could negatively impact Icon's financial performance. The company's reliance on consistent revenue growth from clinical research is further complicated by external factors such as inflation and a slowdown in pharmaceutical R&D spending, adding to the negative outlook for its stock.
This aggregate rating is based on analysts' research of ICON and is not a guaranteed prediction by Public.com or investment advice.
ICON (ICLR) Analyst Forecast & Price Prediction
Start investing in ICON (ICLR)
Order type
Buy in
Order amount
Est. shares
0 shares